As the global leader in generic and biosimilar medicines, Sandoz is committed to its purpose of "pioneering access for patients" and has benefited over 900 million patients worldwide with ...

Ad-hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules ...

Under the terms of the agreement, Sandoz has exclusive commercial rights for a biosimilar of ipilimumab in Australia, Canada, Europe, Japan and the US. The core sequence patent for ipilimumab ...

Agreement offers rights to commercialize proposed biosimilar of Yervoy®* for treatment of variety of cancer types, targeting net reference medicine sales of USD 2.5 billion[1] Henlius to develop and ...

LONDON (Reuters) -The chief executive of generic drugmaker Sandoz (SIX:SDZ) said a proposal by the CEOs of Novartis (SIX:NOVN) and Sanofi (NASDAQ:SNY) to introduce a Europe-wide list price for new ...

LONDON (Reuters) -The chief executive of generic drugmaker Sandoz said a proposal by the CEOs of Novartis and Sanofi to introduce a Europe-wide list price for new medicines is "deeply flawed" and ...

LONDON (Reuters) -The chief executive of generic drugmaker Sandoz said a proposal by the CEOs of Novartis and Sanofi to introduce a Europe-wide list price for new medicines is "deeply flawed" and ...

Sandoz CEO slams EU-wide drug price proposal, warns US tariffs will hurt patient access The chief executive of generic drugmaker Sandoz said a proposal by the CEOs of Novartis and Sanofi to ...

The increasing prevalence of antibiotic resistance in pathogenic bacteria poses a great healthcare problem worldwide. Azithromycin (AZM) is a very effective macrolide antibiotic to treat many ...